How Alternate Funding Programs Can Ease The Cost Burden Of Specialty Drugs

With specialty drug costs rising, and hundreds more expected to enter the market in 2022, employer groups need innovative alternate funding solutions and a collaborative PBM partner to guide them.

Thumbnail of How Alternate Funding Programs Can Ease The Cost Burden Of Specialty Drugs

How Alternative Funding Programs Can Ease The Cost Burden Of Specialty Drugs

Imagine being prescribed medication for the management of a debilitating chronic condition that costs $6,000 a month. A far cry from a $30 copay. For people battling complex and rare conditions such as Crohn’s disease, rheumatoid arthritis, cancer and multiple sclerosis, high drug costs are becoming the norm.

In this Forbes Business Council article by IPM/PharmAvail President and COO Rich Adams, learn how alternative funding can help make these important drugs more affordable for patients and employers:

https://www.forbes.com/sites/forbesbusinesscouncil/2021/10/13/how-alternative-funding-programs-can-ease-the-cost-burden-of-specialty-drugs/?sh=4e348c5d595b